Why Evolv Technologies Fell Even As Sales Rose

Evolv Technologies just secured U.S. Department of Homeland Security Safety Act Designation for its eXpedite bag screening system, putting both of its core products on the government’s Qualified Anti-Terrorism Technology list. However, the shareholder story over the prior year reads very differently. For Evolv Technologies shareholders, the loss over the past year was 43.9%, including dividends. If you had bought in back on 23 October 2025, how should this mix of recognition and red ink reshape expectations now?

On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.

Evolv Technologies has already moved. Pinpoint other ways to investigate the theme among 38 AI small caps.

The Two Evolv Technologies Stories Investors Were Debating

The shares cost US$7.95 at the start of the period, and Evolv Technologies sat between two sharply different but credible narratives.

The bullish view put fair value at US$9.50, built on an assumption of 19.8% annual revenue growth as more multi-year deals with public schools and hospitals expanded subscription usage.

The bearish camp saw fair value closer to US$5.50, highlighting the risk that tighter privacy rules and pricing pressure in AI security screening would limit adoption and weaken pricing power.

What The Results Changed For The Evolv Technologies Debate

The clearest data point came from Evolv Technologies reporting Q2 2026 revenue of US$43.8m versus US$32.5m a year earlier, alongside a smaller net loss of US$9.3m and a net margin that improved from a loss of 124.6% to a loss of 21.3%. That supported the focus on subscription scale, yet profitability remained unproven, so the evidence cut both ways.

The lesson is simple. When a story relies on expectations of future margin expansion, track net margin and absolute profit together, not just sales, to see if the path toward those economics is actually forming.

What Evolv Technologies’ Lower Price Now Asks You To Believe

Evolv Technologies shares are now at US$4.62, after a 43.9% loss over the past year. The selected Narrative places its Fair Value above that quote, framing the current level as not fully reflecting the subscription base and cash flow profile.

The core argument leans on converting a small slice of potential doorways into long contracts and managing supply chain, contract mix and refurbishment costs. For that view to hold, a buyer today must assume recurring agreements scale faster than these operational headwinds erode margin quality.

"The main condition for success is that Evolv converts its under 5% penetration of an estimated 700,000 serviceable doorways and growing multi-vertical footprint into long-lived subscription contracts supported by its AI data moat and manufacturing scale."

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for

Go Straight To The Source

The next headline does not have to be where your research begins. Go straight to the companies and see whether a contrarian opportunity could be taking shape.

• Company 1 - 30% below our estimate - uses tight vessel supply and multi year projects to support day rates.
• Company 2 - 43% below our estimate - scales trackers and newer storage offerings as a larger backlog shifts mix.
• Company 3 - 35% below our estimate - extends margin work through aftermarket expansion and integrating a higher margin valves business.

Those are three of them. See the full list of 29 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com